NeuroSense ALS Trial Shows Significant Survival Benefit
Ticker: NRSNW · Form: 6-K · Filed: Jul 9, 2024 · CIK: 1875091
Sentiment: bullish
Topics: clinical-trial-results, als, pharmaceuticals
TL;DR
NeuroSense's ALS drug combo shows major survival improvement in trial, potentially a game-changer.
AI Summary
On July 9, 2024, NeuroSense Therapeutics Ltd. announced positive results from its PARADIGM Phase 2b clinical trial for Amyotrophic Lateral Sclerosis (ALS). The trial showed up to a 73% improvement in complication-free survival and a statistically significant slowing of disease progression in patients treated with their drug combination.
Why It Matters
These positive clinical trial results could lead to a new treatment option for ALS patients, a devastating neurodegenerative disease with limited therapeutic choices.
Risk Assessment
Risk Level: medium — While the results are promising, the drug still needs to complete further clinical trials and gain regulatory approval before it can be made available to patients.
Key Numbers
- 73% — Improved Complication-Free Survival (Demonstrated in the PARADIGM ALS clinical trial)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant and company conducting the trial
- PARADIGM (trial) — Name of the Phase 2b clinical trial
- Amyotrophic Lateral Sclerosis (ALS) (disease) — Disease being treated in the trial
- July 9, 2024 (date) — Date of the press release and announcement
FAQ
What was the primary outcome of the PARADIGM Phase 2b clinical trial?
The PARADIGM Phase 2b clinical trial demonstrated up to a 73% improvement in complication-free survival and a statistically significant slowing of disease progression.
What disease is NeuroSense Therapeutics targeting with its PARADIGM trial?
NeuroSense Therapeutics is targeting Amyotrophic Lateral Sclerosis (ALS) with its PARADIGM trial.
When did NeuroSense Therapeutics issue the press release regarding the trial results?
NeuroSense Therapeutics issued the press release on July 9, 2024.
What is the name of the company filing this report?
The company filing this report is NeuroSense Therapeutics Ltd.
What form is this SEC filing?
This SEC filing is a Form 6-K.
Filing Stats: 275 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-07-09 09:29:52
Filing Documents
- ea0209065-6k_neurosense.htm (6-K) — 11KB
- ea020906501ex99-1_neurosense.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 27KB
- 0001213900-24-059941.txt ( ) — 69KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: July 9, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3